The clinical significance of anti-heat shock cognate protein 71 antibody in myasthenia gravis

Journal of Clinical Neuroscience

Volumn 15, Issue 2, 2008, Pages 158-165

  Munakata, Shin ^a   Chen, Mei ^a   Aosai, Fumie ^a   Kawaguchi, Naoki ^a   Nemoto, Yuko ^a   Norose, Kazumi ^a   Hattori, Takamichi ^a   Yano, Akihiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Anti heat shock cognate protein 71 antibody; Autoantibody; Autoimmune disease; FK 506; Heat shock protein; Myasthenia gravis; Tacrolimus

Indexed keywords

CHOLINESTERASE INHIBITOR; CORTICOSTEROID; HEAT SHOCK COGNATE PROTEIN 71; HEAT SHOCK COGNATE PROTEIN 71 ANTIBODY; HEAT SHOCK PROTEIN; PREDNISONE; PROTEIN ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; SAMPLING; SCORING SYSTEM; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADRENAL CORTEX HORMONES; ADULT; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HSC70 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; STATISTICS AS TOPIC;

EID: 37349114503     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2006.07.006     Document Type: Article

References (41)

1. Drachman D.B. Myasthenia gravis. N Engl J Med 330 (1994) 1797-1810
2. Oosterhuis H.J.G.H., Limburg P.C., Hummel-Tappel E., et al. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci 58 (1983) 371-385
3. Kuks J.B.M., Oosterhuis H.J.G.H., Limburg P.C., et al. Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmun 4 (1991) 197-211
4. Komiya T., and Sato T. Long-term follow-up study of relapse in symptoms and reelevation of acetylcholine receptor antibody titers in patients with myasthenia gravis. Ann N Y Acad Sci 540 (1988) 605-607
5. Vincent A., Bowen J., Newsom-Davis J., et al. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2 (2003) 99-106
6. Romi F., Aarli J.A., and Gilhus N.E. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 12 (2005) 413-418
7. Oosterhuis H.J.G.H. Myasthenia gravis. A survey. Clin Neurol Neurosurg 83 (1981) 105-135
8. Egerton M., Scollay R., and Shortman K. Kinetics of mature T-cell development in the thymus. Proc Natl Acad Sci USA 87 (1990) 2579-2582
9. Nagvekar N., Moody A.M., Moss P., et al. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 101 (1998) 2268-2277
10. Fujii Y., Monden Y., Hashimoto J., et al. Acetylcholine receptor antibody production by bone marrow cells in a patient with myasthenia gravis. Neurology 35 (1985) 577-579
11. - (double-negative) T cells after thymectomy parallels clinical remission in myasthenia gravis associated with thymic hyperplasia but not thymoma. Ann Neurol 48 (2000) 603-608
12. Marinó M., Ricciardi R., Pinchera A., et al. Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab 82 (1997) 438-443
13. Aarli J.A., Milde E.J., and Thunold S. Arthritis in myasthenia gravis. J Neurol Neurosurg Psychiatry 38 (1975) 1048-1055
14. Lamian V., Small G.M., and Feldherr C.M. Evidence for the existence of a novel mechanism for the nuclear import of HSC70. Exp Cell Res 228 (1996) 84-91
15. Flynn G.C., Chappell T.G., and Rothman J.E. Peptide binding and release by proteins implicated as catalysts of protein assembly. Science 245 (1989) 385-390
16. Lindquist S., and Craig E.A. The heat-shock proteins. Annu Rev Genet 22 (1988) 631-677
17. Hartl F.U. Molecular chaperones in cellular protein folding. Nature 381 (1996) 571-580
18. Conroy S.E., Tucker L., Latchman D.S., et al. Incidence of anti Hsp 90 and 70 antibodies in children with SLE, juvenile dermatomyositis and juvenile chronic arthritis. Clin Exp Rheumatol 14 (1996) 99-104
19. Minota S., Cameron B., Welch W.J., et al. Autoantibodies to the constitutive 73-kD member of the hsp70 family of heat shock proteins in systemic lupus erythematosus. J Exp Med 168 (1988) 1475-1480
20. Mairesse N., Kahn M.F., and Appelboom T. Antibodies to the constitutive 73-kd heat shock protein: A new marker of mixed connective tissue disease?. Am J Med 95 (1993) 595-600
21. Hayem G., De Bandt M., Palazzo E., et al. Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Ann Rheum Dis 58 (1999) 291-296
22. Ohguro H., Ogawa K., Maeda T., et al. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci 40 (1997) 3160-3167
23. Norose K., Mun H.-S., Chen M., et al. Serum antibodies to HSC71 in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 84 (2000) 1434-1435
24. Lindstrom J.M., Seybold M.E., Lennon V.A., et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
25. Lindstrom J. Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome. Ann Rev Immunol 3 (1985) 109-131
26. Jaretzki III A., Barohn R.J., Ernstoff R.M., et al. Myasthenia gravis : Recommendations for clinical research standards. Neurology 55 (2000) 16-23
27. Wolfe G.I., Herbelin L., Nations S.P., et al. Myasthenia gravis activities of daily living profile. Neurology 52 (1999) 1487-1489
28. Barohn R.J., McIntire D., Herbelin L., et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 841 (1998) 769-772
29. Chen M., Aosai F., Mun H.-S., et al. Anti-HSP70 autoantibody formation by B-1 cells in Toxoplasma gondii-infected mice. Infect Immun 68 (2000) 4893-4899
30. H1 B-1 cells in Toxoplasma gondii-infected mice. Int Immunol 15 (2003) 39-47
31. + CTL. Microbiol Immunol 41 (1997) 553-561
32. van Eden W., van der Zee R., Paul A.G.A., et al. Do heat shock proteins control the balance of T-cell regulation in inflammatory disease?. Immunol Today 19 (1998) 303-307
33. Georgopoulos C., and Welch W.J. Role of the major heat shock proteins as molecular chaperones. Annu Rev Cell Biol 9 (1993) 601-634
34. Dhillon V.B., McCallum S., Norton P., et al. Differential heat shock protein overexpression and its clinical relevance in systemic lupus erythematosus. Ann Rheum Dis 52 (1993) 436-442
35. Dhillon V., McCallum S., Wilks D., et al. The differential expression of heat shock proteins in rheumatic disease. Br J Rheumatol 32 (1993) 883-892
36. Jarjour W.N., Jeffries B.D., Davis J.S., et al. Autoantibodies to human stress proteins. A survey of various rheumatic and other inflammatory diseases. Arthritis Rheum 34 (1991) 1133-1138
37. Albani S., Tuckwell J.E., Esparza L., et al. The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaJ and the histocompatibility leukocyte antigen DRB10401 molecule. J Clin Invest 89 (1992) 327-331
38. Vincent A., Willcox N., Hill M., et al. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol Rev 164 (1998) 157-168
39. De Baets M., and Stassen M.H.W. The role of antibodies in myasthenia gravis. J Neurol Sci 202 (2002) 5-11
40. Kawaguchi N., Yoshiyama Y., Nemoto Y., et al. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 20 (2004) 1269-1273
41. Ho S., Clipstone N., Timmermann L., et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 80 (1996) S40-S45